Mackenzie Financial Corp Cuts Stake in Catalent, Inc. (NYSE:CTLT)

Mackenzie Financial Corp lessened its stake in shares of Catalent, Inc. (NYSE:CTLT) by 17.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,421 shares of the company’s stock after selling 1,182 shares during the period. Mackenzie Financial Corp’s holdings in Catalent were worth $244,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in CTLT. Gladius Capital Management LP purchased a new stake in shares of Catalent during the 3rd quarter worth approximately $28,000. Exchange Traded Concepts LLC purchased a new position in shares of Catalent during the 3rd quarter valued at $31,000. Cary Street Partners Investment Advisory LLC grew its stake in shares of Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after acquiring an additional 709 shares during the period. PFG Private Wealth Management LLC purchased a new stake in Catalent in the 3rd quarter worth about $155,000. Finally, V Square Quantitative Management LLC purchased a new stake in Catalent in the 3rd quarter worth about $181,000.

Wall Street Analysts Forecast Growth

CTLT has been the subject of a number of research reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. Stephens reiterated an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. StockNews.com started coverage on Catalent in a research report on Saturday. They set a “sell” rating on the stock. UBS Group reiterated a “neutral” rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Finally, Barclays increased their price objective on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $52.46.

Catalent Trading Up 0.2 %

CTLT stock opened at $55.92 on Monday. Catalent, Inc. has a one year low of $31.45 and a one year high of $60.20. The company has a market capitalization of $10.12 billion, a PE ratio of -8.22, a price-to-earnings-growth ratio of 6.03 and a beta of 1.20. The company’s 50 day moving average price is $56.68 and its two-hundred day moving average price is $48.71. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the prior year, the firm posted $0.62 EPS. The firm’s quarterly revenue was down 10.2% on a year-over-year basis. As a group, analysts predict that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.